A prospective study of prognostic value of type IV collagenase activity in colorectal cancer tissue

Digestive Diseases and Sciences

Volumn 42, Issue 8, 1997, Pages 1660-1665

  Ambiru, Satoshi ^a   Miyazaki, Masaru ^a   Ito, Hiroshi ^a   Nakagawa, Koji ^a   Shimizu, Hiroaki ^a   Nukui, Yuji ^a   Nozawa, Satoshi ^a   Okuno, Atsushi ^a   Yoshitomi, Hideyuki ^a   Nakajima, Nobuyuki ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Prognostic factor; Type IV collagenase

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; COLLAGENASES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 9844245131     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018801229372     Document Type: Article

References (33)

1. Dukes CE, Bussey HJR: The spread of rectal cancer and its effect on prognosis. Br J Cancer 12:309-320, 1958
2. Griffin MR, Bergstralh EJ, Coffey RJ, Beart RW, Melton LJ III: Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 60:2318-2324, 1987
3. Wiggers T, Arends JW, Schutte B, Volovics L, Bosman PT: A mullivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer 61:386-395, 1998
4. de Leon MP, Sant M, Micheli A, Sacchetti C, Di Gregorio C, Fante R, Zanghieri G, Melotti G, Gatta G: Clinical and pathologic prognostic indicators in colorectal cancer. Cancer 69:626-635, 1992
5. Wanebo HJ, Rao B, Pinsky CM, Hoffman RG, Stearns M, Schwartz MK, Oettgen HF: Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 299:448-451, 1978
6. Filella X, Molina R, Grau JJ, Pique JM, Garcia-Valdecasas JC, Astudillo E, Biete A, Bordas JM, Novell A, Campo E, Ballesta AM: Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg 216:55-59, 1992
7. Al-Sheneber IF, Shibata HR, Sampalis J, Jothy S: Prognostic significance of proliferating cell nuclear antigen expression in colorectal cancer. Cancer 71:1454-1459, 1993
8. a as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer 75:2051-2056, 1995
9. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, Sheahan K: Urokinase-type plasminogen activator and outcome in Dukes' B coloreetal cancer. Lancet 344:583-584, 1994
10. Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, Stetler-Stevenson WG: Increased expression of the Mr 72.000 type IV collagenase in human colonie adenocarcinoma. Cancer Res 51:439-444, 1991
11. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F: Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53:5365-5369, 1993
12. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR: Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67:1126-1131, 1993
13. Liotta LA, Rao CN, Barsky SH: Tumor invasion and the extracellular matrix. Lab Invest 49:636-648, 1983
14. Liotta LA: Tumor invasion and metastases: Role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res 46:1-7, 1986
15. Bresalier RS, Hujanen ES, Raper SE, Roll FJ, Itzkowitz SH, Martin GR, Kim YS: An animal model for colon cancer metastasis: Establishment and characterization of murine cell lines with enhanced liver-metastasizing ability. Cancer Res 47:139S-1406, 1987
16. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F: Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56:190-196, 1996
17. Dukes CE: The classification of cancer of the rectum. J Pathol Bacteriol 35:323-332, 1932
18. Kubochi K, Otani Y, Maruyama K, Okazaki I: Development of a direct measurement assay for collagenase against type I and type IV collagens in tissue homogenate and its application in stomach and lung cancers. In Proteinases in Inflammation and Tumor Invasion. H Tschesche (ed). Berlin, Walter de Gruyter, 1986, pp 337-356
19. Liotta LA, Tryggvason K, Garbisa S, Robey PG, Abe S: Partial purification and characterization of a neutral protease which cleaves type IV collagen. Biochemistry 20:100-104, 1981
20. Maruyama K, Feinman L, Okazaki I, Lieber CS: Direct measurement of neutral collagenase activity in homogenates from baboon and human liver. Biochim Biophys Acta 658:124-131, 1981
21. Lowry OH, Rosebrough NJ, Farr AL: Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275, 1951
22. Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, Paolucci F, Pau B, Rasmussen BB, Rose C: Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49:6008-6014, 1989
23. Bernhard EJ, Gruber SB, Muschel RJ: Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/ collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 91:4293-4297, 1994
24. Ambiru S, Miyazaki M, Ito H, Kaiho T, Ando K, Otawa S, Ogata A, Hayashi S, Yasuda N, Sarashina H, Nakajima N: Type IV collagenase activities in human colorectal cancers and its role in cancer invasion and metastasis. Jpn J Gastroenterol 90:1555-1561, 1993
25. Ambiru S, Miyazuki M, Nakagawa K, Nakajima N: Increased serum type IV collagen 7-S levels in patients with hepatic metastasis. Am J Gastroenterol 90:783-787, 1995
26. Stetler-Stevenson WG, Krutzsch HC, Wacher MP, Margulies IMK, Liotta LA: The activation of human type IV collagenase proenzyme. J Biol Chem 264:1353-1356, 1989
27. Howard EW, Bullen EC, Banda MJ: Regulation of the autoactivation of human 72-kDa progelatinase by tissue inhibitor of metalloproteinases-2. J Biol Chem 266:13064-13069, 1991
28. Howard EW, Bullen EC, Banda MJ: Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. J Biol Chem 266:13070-13075, 1991
29. Alvarez OA, Carmichael DF, DeClerck YA: Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 82:589-595, 1990
30. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG: Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83:775-779, 1991
31. Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G, Denhardt DT: Antisense RNA-induced reduction in murinc TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 243:947-950, 1989
32. Khokha R: Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 86:299-304, 1994
33. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown PD, Giavazzi R: Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87:293-298, 1995